Affiliations: [a] Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Doiwala, Dehradun, Uttarakhand, India | [b] Department of Surgical Oncology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Doiwala, Dehradun, Uttarakhand, India
Correspondence:
[*]
Corresponding author: Smita Chandra MD, Professor, Department of Pathology, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Doiwala, Dehradun-248140, Uttarakhand, India. Tel.: +91 9411718455; E-mail: smita_harish@yahoo.com. ORCID: https://orcid.org/0000-0002-0652-4708
Abstract: ER−/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis. Therefore, the present two cases of controversial subtype ER−/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.
Keywords: Breast carcinoma, ER−, PR+, molecular subtype
DOI: 10.3233/BD-230039
Journal: Breast Disease, vol. 42, no. 1, pp. 315-318, 2023
